Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3792902 | 0.95 | SYK (0.84) | SYKCD63 | |
| SCHEMBL3795702 | 0.94 | SYK (0.82) | SYKCD63 | |
| SCHEMBL4331944 | 0.93 | SYK (1.00) | SYKCD63 | |
| SCHEMBL3784294 | 0.92 | SYK (1.00) | SYKCD63 | |
| SCHEMBL3790305 | 0.92 | SYK (0.91) | SYKCD63 | |
| SCHEMBL3801821 | 0.90 | SYK (0.86) | SYKCD63 | |
| SCHEMBL13703284 | 0.89 | SYK (0.87) | SYKCD63 | |
| SCHEMBL4332219 | 0.89 | SYK (0.83) | SYKCD63 | |
| SCHEMBL3805099 | 0.89 | SYK (0.85) | SYKCD63 | |
| SCHEMBL4323328 | 0.89 | SYK (1.00) | SYKCD63 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221612-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Kronos Bio, Inc. | 2009-09-03 | — | — | US | claimed |
| US-8697699-B2 | Imidazopyrazine SYK inhibitors | GILEAD CONNECTICUT, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20130023499-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-20130023499-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-20130023499-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| EP-2252617-A1 | 6-ARYL-IMIDAZ0[L, 2-A]PYRAZINE DERIVATIVES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI Pharmaceuticals, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20090221612-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Kronos Bio, Inc. | 2009-09-03 | — | — | US | disclosed |
| US-20090221612-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Kronos Bio, Inc. | 2009-09-03 | — | — | US | disclosed |
| US-20090221612-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Kronos Bio, Inc. | 2009-09-03 | — | — | US | disclosed |
| WO-2009102468-A1 | 6-ARYL-IMIDAZ0[L, 2-A] PYRAZINE DERIVATIVES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023499-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | SYK, MYD88, BTK | SYK 1/4885CD63 2609/4885 |
| US-20090221612-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | SYK, MYD88, BTK | SYK 1/4885CD63 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.